Chemical Compound

Gadolinium, [6,9-bis[(carboxy-?O)methyl]-3-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-11-(oxo-?O)-15-oxa-3,6,9,12-tetraazahexadecanoato(3-)-?N3,?N6,?N9,?O1]-; Gadolinium, [8,11-bis[(carboxy-?O)methyl]-14-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-6-(oxo-?O)-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)-?N8,?N11,?N14,?O16]- (9CI); 2-Oxa-5,8,11,14-tetraazahexadecan-16-oic acid, 8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-, gadolinium complex; Gadolinium, [8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)]-; [6,9-Bis[(carboxy-?O)methyl]-3-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-11-(oxo-?O)-15-oxa-3,6,9,12-tetraazahexadecanoato(3-)-?N3,?N6,?N9,?O1]gadolinium; Gadoversetamide; Gd-DTP-BMEA; MP 1177; OptiMARK; [N,N-Bis[2-[[(Carboxymethyl)[(2-methoxyethyl)carbamoyl]methyl]amino]ethyl]glycinato(3

CAS Registry Number 131069-91-5
Gadolinium, [6,9-bis[(carboxy-?O)methyl]-3-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-11-(oxo-?O)-15-oxa-3,6,9,12-tetraazahexadecanoato(3-)-?N3,?N6,?N9,?O1]-; Gadolinium, [8,11-bis[(carboxy-?O)methyl]-14-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-6-(oxo-?O)-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)-?N8,?N11,?N14,?O16]- (9CI); 2-Oxa-5,8,11,14-tetraazahexadecan-16-oic acid, 8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-, gadolinium complex; Gadolinium, [8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)]-; [6,9-Bis[(carboxy-?O)methyl]-3-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-11-(oxo-?O)-15-oxa-3,6,9,12-tetraazahexadecanoato(3-)-?N3,?N6,?N9,?O1]gadolinium; Gadoversetamide; Gd-DTP-BMEA; MP 1177; OptiMARK; [N,N-Bis[2-[[(Carboxymethyl)[(2-methoxyethyl)carbamoyl]methyl]amino]ethyl]glycinato(3 结构式
Primary record

Gadolinium, [6,9-bis[(carboxy-?O)methyl]-3-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-11-(oxo-?O)-15-oxa-3,6,9,12-tetraazahexadecanoato(3-)-?N3,?N6,?N9,?O1]-; Gadolinium, [8,11-bis[(carboxy-?O)methyl]-14-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-6-(oxo-?O)-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)-?N8,?N11,?N14,?O16]- (9CI); 2-Oxa-5,8,11,14-tetraazahexadecan-16-oic acid, 8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-, gadolinium complex; Gadolinium, [8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)]-; [6,9-Bis[(carboxy-?O)methyl]-3-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-11-(oxo-?O)-15-oxa-3,6,9,12-tetraazahexadecanoato(3-)-?N3,?N6,?N9,?O1]gadolinium; Gadoversetamide; Gd-DTP-BMEA; MP 1177; OptiMARK; [N,N-Bis[2-[[(Carboxymethyl)[(2-methoxyethyl)carbamoyl]methyl]amino]ethyl]glycinato(3

库存
6,064 克
纯度
99.6 %
CAS
131069-91-5

化合物标识与属性

CAS
131069-91-5
PubChem CID
6435809
SMILES
COCCNC(=O)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]
Canonical SMILES
COCCNC(=O)CN(CCN(CCN(CC(=O)[O-])CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-].[Gd+3]

名称与同义词

  • GADOVERSETAMIDE
  • Optimark
  • UNII-RLM74T3Z9D
  • Optimark In Plastic Container
  • RLM74T3Z9D
  • HSDB 7550
  • Gadoversetamide [USAN:INN:BAN]
  • DTXSID10156865
  • GADOVERSETAMIDE (200 MG)
  • Gadoversetamide [USAN:USP:INN:BAN]
  • HY-A0196
  • C20-H34-Gd-N5-O10
  • CID6435809
  • MP-1177
  • LS-186531
  • CS-0017542
  • 131069-91-5
  • (Gadoversetamide) (8,11-bis(carboxymethyl)-14-(2-((2-methoxyethyl)amino)-2-oxoethyl)-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)), gadolinium
  • (N,N-Bis(2-((carboxymethyl)(((2-methoxyethyl)carbamoyl)methyl)amino)ethyl)glycinato(3-))gadolinium
  • (8,11-bis(carboxymethyl)-14-(2-((2-methoxyethyl)amino)-2-oxoethyl)-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)), gadolinium
  • {8,11-Bis[(carboxylato-kappaO)methyl]-14-{2-[(2-methoxyethyl)amino]-2-(oxo-kappaO)ethyl}-6-(oxo-kappaO)-2-oxa-5,8,11,14-tetraazahexadecan-16-oato-kappa~4~N~8~,N~11~,N~14~,O~16~}gadolinium
  • Gadolinium, [6,9-bis[(carboxy-?O)methyl]-3-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-11-(oxo-?O)-15-oxa-3,6,9,12-tetraazahexadecanoato(3-)-?N3,?N6,?N9,?O1]-; Gadolinium, [8,11-bis[(carboxy-?O)methyl]-14-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-6-(oxo-?O)-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)-?N8,?N11,?N14,?O16]- (9CI); 2-Oxa-5,8,11,14-tetraazahexadecan-16-oic acid, 8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-, gadolinium complex; Gadolinium, [8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)]-; [6,9-Bis[(carboxy-?O)methyl]-3-[2-[(2-methoxyethyl)amino]-2-(oxo-?O)ethyl]-11-(oxo-?O)-15-oxa-3,6,9,12-tetraazahexadecanoato(3-)-?N3,?N6,?N9,?O1]gadolinium; Gadoversetamide; Gd-DTP-BMEA; MP 1177; OptiMARK; [N,N-Bis[2-[[(Carboxymethyl)[(2-methoxyethyl)carbamoyl]methyl]amino]ethyl]glycinato(3